NCT00189813已完成2 期
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Potential Efficacy, Safety and Tolerability of Different Oral Doses of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 691
- 试验地点
- 45
研究概览
简要总结
This study will examine the efficacy, safety and tolerability of different oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient meets Rome II criteria for IBS and the subgroup of diarrhea predominant IBS
排除标准
- •Patient with severe cardiovascular disease, respiratory diseases, renal diseases, hepatic diseases, digestive tract diseases (excluding IBS), blood diseases, or neurological or psychiatric diseases
- •Patient reported having any Type 1 or Type 2 stool on the Bristol Stool Form Scale during the run-in period
研究者
研究点 (45)
Loading locations...
相似试验
已完成
2 期
Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary SyndromesAcute Coronary SyndromeNCT00994292Astellas Pharma Europe B.V.1,276
已完成
2 期
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement SurgeryArthroplasty, Replacement, HipVenous ThromboembolismNCT00902928Astellas Pharma Europe B.V.1,992
已完成
3 期
Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)Irritable Bowel SyndromeNCT00189696Astellas Pharma Inc
已完成
2 期
A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)Overactive BladderNCT00337090Astellas Pharma Inc1,108
终止
1 期
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy SubjectsHealthyNCT03809039Tanabe Pharma America, Inc.52